Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

被引：2
作者：
Toorop, Alyssa A. [1 ]
Rispens, Theo [2 ,3 ,4 ]
Strijbis, Eva M. M. [1 ]
van Oosten, Bob W. [1 ]
de Jong, Brigit A. [1 ]
Uitdehaag, Bernard M. J. [1 ]
Killestein, Joep [1 ]
van Kempen, Zoe L. E. [1 ]
机构：
[1] Vrije Univ Amsterdam, Univ Amsterdam, MS Ctr Amsterdam, Dept Neurol,Med Ctr,Amsterdam Neurosci, Amsterdam, Netherlands
[2] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, Amsterdam, Netherlands
[4] Sanquin Diagnost Serv, Biol Lab, Amsterdam, Netherlands
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 02期
关键词：
Multiple sclerosis; natalizumab; personalized dosing; extended interval dosing; pregnancy; concentrations;
D O I：
10.1177/13524585211052168
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID.
引用
收藏
页码：323 / 326
页数：4
相关论文
共 10 条
  • [1] Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis
    Demortiere, Sarah
    Rico, Audrey
    Maarouf, Adil
    Boutiere, Clemence
    Pelletier, Jean
    Audoin, Bertrand
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) : 712 - 718
  • [2] Pharmacokinetics of drugs in pregnancy
    Feghali, Maisa
    Venkataramanan, Raman
    Caritis, Steve
    [J]. SEMINARS IN PERINATOLOGY, 2015, 39 (07) : 512 - 519
  • [3] Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure
    Flanagan, Emma
    Gibson, Peter R.
    Wright, Emily K.
    Moore, Gregory T.
    Sparrow, Miles P.
    Connell, William
    Kamm, Michael A.
    Begun, Jakob
    Christensen, Britt
    De Cruz, Peter
    Shelton, Edward
    Dowling, Damian
    Andrews, Jane M.
    Brown, Steven J.
    Niewiadomski, Olga
    Ward, Mark G.
    Rosella, Ourania
    Rosella, Gennaro
    Kiburg, Katerina V.
    Ross, Alyson L.
    Bell, Sally J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (10) : 1551 - 1562
  • [4] Natalizumab Use During the Third trimester of Pregnancy
    Haghikia, Aiden
    Langer-Gould, Annette
    Rellensmann, Georg
    Schneider, Henriette
    Tenenbaum, Tobias
    Elias-Hamp, Birte
    Menck, Sylvia
    Zimmermann, Julian
    Herbstritt, Sandra
    Marziniak, Martin
    Kuempfel, Tania
    Meinl, Ingrid
    Plavina, Tatiana
    Gold, Ralf
    Hellwig, Kerstin
    [J]. JAMA NEUROLOGY, 2014, 71 (07) : 891 - 895
  • [5] Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
    Khatri, B. O.
    Man, S.
    Giovannoni, G.
    Koo, A. P.
    Lee, J. -C.
    Tucky, B.
    Lynn, F.
    Jurgensen, S.
    Woodworth, J.
    Goelz, S.
    Duda, P. W.
    Panzara, M. A.
    Ransohoff, R. M.
    Fox, R. J.
    [J]. NEUROLOGY, 2009, 72 (05) : 402 - 409
  • [6] Polman Chris H, 2006, N Engl J Med, V354, P899
  • [7] Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks
    Portaccio, Emilio
    Moiola, Lucia
    Martinelli, Vittorio
    Annovazzi, Pietro
    Ghezzi, Angelo
    Zaffaroni, Mauro
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Rinaldi, Francesca
    Gallo, Paolo
    Tortorella, Carla
    Paolicelli, Damiano
    Pozzilli, Carlo
    De Giglio, Laura
    Cavalla, Paola
    Cocco, Eleonora
    Marrosu, Maria Giovanna
    Solaro, Claudio
    Uccelli, Antonio
    Laroni, Alice
    Pasto, Luisa
    Giannini, Marta
    Trojano, Maria
    Comi, Giancarlo
    Amato, Maria Pia
    [J]. NEUROLOGY, 2018, 90 (10) : E832 - E839
  • [8] Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody
    Rispens, Theo
    van Leeuwen, Astrid
    Vennegoor, Anke
    Killestein, Joep
    Aalberse, Rob C.
    Wolbink, Gerrit J.
    Aarden, Lucien A.
    [J]. ANALYTICAL BIOCHEMISTRY, 2011, 411 (02) : 271 - 276
  • [9] Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
    van Kempen, Zoe L. E.
    Hoogervorst, Erwin L. J.
    Wattjes, Mike P.
    Kalkers, Nynke F.
    Mostert, Jop P.
    Lissenberg-Witte, Birgit I.
    de Vries, Annick
    ten Brinke, Anja
    van Oosten, Bob W.
    Barkhof, Frederik
    Teunissen, Charlotte E.
    Uitdehaag, Bernard M. J.
    Rispens, Theo
    Killestein, Joep
    [J]. NEUROLOGY, 2020, 95 (06) : E745 - E754
  • [10] Pharmacodynamics of natalizumab extended interval dosing in MS
    Zhovtis Ryerson, Lana
    Li, Xiaochun
    Goldberg, Judith D.
    Hoyt, Tamara
    Christensen, Angel
    Metzger, Ryan R.
    Kister, Ilya
    Foley, John
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (02):
1